Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina.

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina. In an exchange filing, the company stated that the authorities conducted a Good Manufacturing Practice inspection at the facility between June 9-17.

Outcome of Inspection

Glenmark said that the FDA has issued a Form 483 upon the conclusion of its inspection at the manufacturing facility. The federal agency reported five observations in its report; however, the company said that there was no observation on data integrity, and all five observations were procedural in nature.

Glenmark stated that it will work with the Food and Drug Administration to address the observations by the agency. Furthermore, the company will respond to the FDA within a stipulated timeline.

Glenmark gets DCGI approval for cancer medicine

Earlier on June 9, Glenmark Pharmaceuticals received approval from the Drugs Controller General of India (DCGI) for Zanubrutinib, an oncology medicine. The medicine developed by US-based pharmaceutical company, BeOne Medicines, will be marketed by Glenmark under the brand name BRUKINSA.

The cancer medicine launched by Glenmark is known for its high response rate and lower cardiac event rate. According to Glenmark, BRUKINSA has a 1.9 percent serious cardiac event rate against the industry average of 7.7 percent serious cardiac event rate.

Glenmark’s share price

In the past month, Glenmark Pharmaceuticals’ stock has gained 15.40 percent . On Wednesday, Glenmark’s share was up by 0.42 percent at Rs 1,660 per share, by 1 PM.

Related Posts

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

The Court observed that the alleged short supply of one tablet, coupled with the collection of ₹1.12, did not establish that the accused had sold the drug at a price…

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

MEERUT/SHIMLA: An illegal pharmaceutical factory allegedly manufacturing counterfeit medicines used to treat epilepsy, diabetes, typhoid and other ailments using substances such as chalk and lactose was busted in Himachal Pradesh’s…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Karnataka High Court quashes case against MedPlus over short supply of one tablet costing ₹1.12

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Fake epilepsy, diabetes drugs made using chalk, lactose at illegal Himachal factory; 2 held

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital